HGSI - Human Genome Sciences, Inc.

HGSI (Human Genome Sciences, Inc.)

• Entry price: $14
• Risk Level:  9
• Profit Potential: 9
• 1 yr Target Price: $25-$35

According to Yahoo Finance, Analysts estimate a 93.9% growth this year.

With substantial financial rights to certain products in GlaxoSmithKline, Amgen, Genentech and Roche’s line of drugs, all are major players in the clinical drug industry; HGS is a hot stock to buy.  Some of these drugs include darapladib(in Phase III development as a treatment for coronary heart disease) and Syncria (albiglutide)(in Phase III development as a treatment for type 2 diabetes).  Both of these drugs are promising and have high potential to send stock prices up.

Furthermore, HGS has a strategic agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of ZALBIN™ (formerly Albuferon®) which has completed Phase 3 development in chronic hepatitis C.  They are expecting to submit global marketing applications in fall 2009.

Another promising drug in the late stages of development is BENLYSTA™ (formerly LymphoStat-B®).  HGS successfully completed the initial Phase 3 trial treatment of systemic lupus and results of the second BENLYSTA Phase 3 trial are also expected in November 2009.

In the first half of 2009, HGS achieved its first product revenues of $162.7 million when they delivered raxibacumab (ABthrax(TM)) to the U.S. Strategic National Stockpile for the treatment of inhalation anthrax. In July 2009, HGS also secured a new purchase order for 45,000 doses of raxibacumab to be delivered to the U.S. Strategic National Stockpile over a three-year period.

Having one already commercialized drug, two in the process to be commercialized in fall 2009 and 2 high potential drugs in development make HGS a great short term buy.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.